Trial Profile
Pilot Study of MPDL3280A Plus Stereotactic Ablative Radiotherapy (SAR) in Stage IV Non-small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 10 Aug 2022
Price :
$35
*
At a glance
- Drugs Atezolizumab (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- 02 Aug 2022 Status changed from active, no longer recruiting to discontinued.
- 15 Jul 2021 Planned End Date changed from 1 Sep 2021 to 1 Jun 2022.
- 15 Jul 2021 Planned primary completion date changed from 1 Mar 2021 to 1 Dec 2021.